TY - JOUR
T1 - Nanomedicine Strategies Utilizing Lipid-Based Nanoparticles for Liver Cancer Therapy
T2 - Exploring Signaling Pathways and Therapeutic Modalities
AU - Asgharzadeh, Fereshteh
AU - Binabaj, Maryam Moradi
AU - Fanoudi, Sahar
AU - Cho, William C.
AU - Yang, Yu Jeong
AU - Azarian, Maryam
AU - Ardestani, Mehdi Shafiee
AU - Nasiri, Nasim
AU - Farani, Marzieh Ramezani
AU - Huh, Yun Suk
N1 - Publisher Copyright:
© 2024 The Author (s).
PY - 2024
Y1 - 2024
N2 - Liver cancer, specifically hepatocellular carcinoma (HCC), is the second leading cause of cancer-related deaths, following pancreatic cancer. The 5-year overall survival rate for HCC remains relatively low. Currently, there are multiple treatment options available for HCC, including systemic drugs, minimally invasive local therapies such as radiofrequency ablation, transarterial chemoembolization (TACE), and arterial radioembolization (TARE), as well as surgical interventions like liver resection or transplantation. However, the effectiveness of drug delivery to the cancerous liver is hindered by pathophysiological changes in the organ. In order to address this challenge, lipid-based nanoparticles (LNPs) have emerged as promising platforms for delivering a diverse range of therapeutic drugs. LNPs offer various structural configurations that enhance their physical stability and enable them to accommodate different types of cargo with varying mechanical properties and degrees of hydrophobicity. In this article, we provide a comprehensive review of the current applications of LNPs in the development of anti-HCC therapies. By examining the existing research, we aim to shed light on the potential future directions and advancements in this field.
AB - Liver cancer, specifically hepatocellular carcinoma (HCC), is the second leading cause of cancer-related deaths, following pancreatic cancer. The 5-year overall survival rate for HCC remains relatively low. Currently, there are multiple treatment options available for HCC, including systemic drugs, minimally invasive local therapies such as radiofrequency ablation, transarterial chemoembolization (TACE), and arterial radioembolization (TARE), as well as surgical interventions like liver resection or transplantation. However, the effectiveness of drug delivery to the cancerous liver is hindered by pathophysiological changes in the organ. In order to address this challenge, lipid-based nanoparticles (LNPs) have emerged as promising platforms for delivering a diverse range of therapeutic drugs. LNPs offer various structural configurations that enhance their physical stability and enable them to accommodate different types of cargo with varying mechanical properties and degrees of hydrophobicity. In this article, we provide a comprehensive review of the current applications of LNPs in the development of anti-HCC therapies. By examining the existing research, we aim to shed light on the potential future directions and advancements in this field.
KW - Hepatocellular carcinoma
KW - Lipid-based nanoparticles
KW - Liver cancer
KW - Nanomedicine
KW - Signaling pathways
KW - Therapeutic approaches
UR - http://www.scopus.com/inward/record.url?scp=85209767484&partnerID=8YFLogxK
U2 - 10.34172/apb.2024.061
DO - 10.34172/apb.2024.061
M3 - Review article
AN - SCOPUS:85209767484
SN - 2228-5881
VL - 14
SP - 513
EP - 523
JO - Advanced Pharmaceutical Bulletin
JF - Advanced Pharmaceutical Bulletin
IS - 3
ER -